|
시장보고서
상품코드
2050766
제네릭 무균 주사제 시장 : 약제 유형별, 치료 용도별, 유통 채널별, 지역별Generic Sterile Injectables Market, by Drug Type, by Therapeutic Application, by Distribution Channel and by Region |
||||||
제네릭 무균 주사제 시장은 2026년에 514억 달러로 추계되고 있으며, 2033년까지 1,047억 1,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.7%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 514억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 10.70% | 2033년 시장 규모 예측 : | 1,047억 1,000만 달러 |
제네릭 무균 주사제는 미국 식품의약국(FDA)의 승인을 받은 생물제제로, 광범위한 헬스케어 산업에서 많은 질병과 장애를 치료하는 데 사용되고 있습니다. 제네릭 무균 주사제는 동종 브랜드 의약품에 비해 매우 저렴하면서도 동등한 효과를 발휘합니다. 따라서 이러한 주사제는 항상 높은 수요가 있으며, 전 세계 대부분의 병원과 클리닉에서 사용되고 있습니다. 그러나 이러한 주사제 제조에 대한 FDA의 엄격한 규제 때문에 글로벌 제네릭 무균 주사제 시장의 주요 기업은 수요를 충족시키는 것이 항상 도전과제로 남아 있습니다.
무균주사제는 수많은 질병과 질환에 적용되므로 제네릭 무균주사제 시장은 가까운 시일 내에 꾸준한 성장이 예상됩니다. 각 제조사들은 제품의 품질 저하 없이 증가하는 수요에 대응하기 위해 제네릭 무균 주사제 생산 확대에 주력하고 있습니다.
시장 역학
시장 기업은 제네릭 무균 주사제 신제품 출시를 위해 노력하고 있으며, 이는 예측 기간 중 글로벌 제네릭 무균 주사제 시장의 성장을 가속화할 것으로 예상됩니다. 예를 들어 2017년 6월, 박스터 인터내셔널(Baxter International)은 염수내 즉시 사용 가능한 클린다마이신 주사액에 대한 미국 식품의약국(FDA)의 승인 및 시판 시작을 발표했습니다. 일반적으로 처방되는 3가지 제형(300mg/50mL, 600mg/50mL, 900mg/50mL)입니다. 클린다마이신은 페니실린이 환자에게 적합하지 않은 경우, 감수성 있는 혐기성 세균이나 연쇄상구균, 폐렴구균, 포도상구균 균주에 의한 심각한 감염에 널리 처방되는 항생제입니다.
주요 기업은 제휴와 같은 비유기적 활동에 집중하고 있으며, 이는 예측 기간 중 글로벌 제네릭 무균 주사제 시장의 성장을 가속화할 것으로 예상됩니다. 예를 들어 2017년 노바티스의 제네릭 사업부인 샌드즈는 시설 개발 및 현대화를 위해 3,354만 달러 이상을 투자하여 슬로베니아에 위치한 항생제 생산 시설을 확장했습니다. 첫 번째 생산라인은 2021년에 가동될 예정이며, 이후 2025년까지 새로운 라인이 단계적으로 도입될 예정입니다.
이 회사는 글로벌 입지를 확대하고 국제적인 상업적 기회를 개선하기 위해 인수와 같은 비유기적 성장 전략을 채택하는 데 주력하고 있습니다. 예를 들어 2016년 8월, 테바 제약산업은 아라간의 제네릭 사업부 인수를 완료했습니다. 아라간은 미국에 본사를 두고 아일랜드에 등록된 제약회사입니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 제네릭 무균 주사제 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 재무 실적, 제품 포트폴리오, 지역적 분포, 유통 전략, 주요 개발 및 전략, 향후 계획 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계의 제네릭 무균 주사제 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 제네릭 무균 주사제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 제네릭 무균 주사제 시장 : 약제 유형별, 2021-2033년
제5장 세계의 제네릭 무균 주사제 시장 : 치료 용도별, 2021-2033년
제6장 세계의 제네릭 무균 주사제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 제네릭 무균 주사제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 섹션
KSA 26.06.10Generic Sterile Injectables Market is estimated to be valued at USD 51.40 Bn in 2026 and is expected to reach USD 104.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 51.40 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.70% | 2033 Value Projection: | USD 104.71 Bn |
The generic sterile injectable are U.S. FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.
The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.
Market Dynamics
Market players are engaged in launching new products for generic sterile injectables, this is expected to increase the growth of the global generic sterile injectables, over the forecast period. For instance, in June 2017, Baxter International Inc. announced the U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations (300mg/50mL, 600mg/50mL, and 900mg/50mL). Clindamycin is a widely prescribed antibiotic for serious infections which is caused by susceptible anaerobic bacteria and strains of streptococci, pneumococci and staphylococci, when penicillin is inappropriate for a patient.
Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in 2017, Novartis' generic arm Sandoz expanded its antibiotic facility in Slovenia, with an investment of over US$ 33.54 million aimed at the development and modernization of facilities. The first production lines started in 2021, after which new lines will be gradually phased in by 2025.
The company is focused on adopting inorganic growth strategies such as acquisitions to expand its global presence and improve international commercial opportunities. For instance, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. Allergan plc.is an American, Irish-domiciled pharmaceutical company.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global generic sterile injectables market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global generic sterile injectables market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global generic sterile injectables market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Vaccines
- Immunoglobulins
- Blood Factors
- Antibiotics
- Others
- By Therapeutic Application (Revenue, USD Bn, 2021 - 2033)
- Cancer
- Metabolic Diseases
- Cardiovascular Diseases
- Central Nervous System Disease
- Infectious Disorders
- Musculoskeletal Disorders
- Others
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Baxter International Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
4. Global Generic Sterile Injectables Market, By Drug Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Generic Sterile Injectables Market, By Therapeutic Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Central Nervous System Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infectious Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Generic Sterile Injectables Market, By Distribution Channel, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Generic Sterile Injectables Market, By Region, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Baxter International Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Fresenius Kabi
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis International AG
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Hikma Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Reddy's Laboratory
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Mylan N.V.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Baxter International Inc.
9. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. Section
- References
- Research Methodology
- About Us and Sales Contact
